Ocugen, Inc.

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
1.690 ^USD	+4.32%		+12.67%	+25.19%

06/11	Ocugen, Inc., Q3 2025 Earnings Call, Nov 05, 2025
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating

Published on 01/24/2024 at 08:09 pm IST - Modified on 01/24/2024 at 08:10 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Ocugen, Inc.

06/11	Ocugen, Inc., Q3 2025 Earnings Call, Nov 05, 2025
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
05/11	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
05/11	Biotech firm Ocugen's Q3 revenue beats expectations	RE
18/25/18	Ocugen Inc says on Sept 16, carisma terminates merger agreement with Ocugen	RE
15/25/15	Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong	MT
15/25/15	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	CI
13/25/13	Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study	MT
13/25/13	Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy	RE
13/25/13	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST--Modifier Gene Therapy for Stargardt Disease	CI
09/25/09	Ocugen announces $20 million registered direct offering of common stock and warrants	RE
04/25/04	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
02/25/02	Ocugen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
01/25/01	Ocugen, Inc., Q2 2025 Earnings Call, Aug 01, 2025
01/25/01	Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln	RE
31/25/31	Ocugen Inc - U.S. court granted co's motion to dismiss securities class action lawsuit - SEC filing	RE
21/25/21	Ocugen, Inc. Announces Appointments to Retina Scientific Advisory Board & Executive Leadership Team	CI
18/25/18	Ocugen, Inc. announces first patient dosed in phase 2/3 Gardian3 pivotal confirmatory trial for OCU410ST--novel modifier gene therapy candidate for Stargardt disease	RE
18/25/18	Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST	CI
23/25/23	Carisma Therapeutics to Merge With OrthoCellix in All-Stock Transaction	MT
16/25/16	Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial	MT
16/25/16	Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of Ocu410st	CI
05/25/05	Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	CI
05/25/05	Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400	MT
05/25/05	Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea	RE

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

Sector

Biotechnology & Medical Research

Calendar

27/03 - Q4 2025 Earnings Release (Projected)

More about the company